Q702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxA New Potential Treatment For Early Prostate Cancer: TGW101
/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by MaxPhase 1 Results: Personalized Cancer Vaccine PGV001 Shows Promise Across Multiple Cancer Types
/in Clinical Trial, Not PCa related/by MaxThe Microbiome: A Frontline Barrier and Emerging Ally in Cancer Treatment
/in Clinical Trial, Not PCa related/by MaxBR111: A New ADC Therapy That Could Work Also For Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxPhase 1 Trial of a Polynucleotide Kinase/Phosphatase (PNKP) Inhibitor
/in Clinical Trial, Not PCa related/by MaxPhase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells
/in Clinical Trial, Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- CRISPR’s New Kill‑Switch: Targeting Cancer Cells by Their RNA Signature May 8, 2026
- A New Immune‑Engaging ADC Platform: STEAP1‑Targeted Vandortuzumab–Exatecan May 7, 2026
- Genetic Maps of Blood Proteins Open New Paths for Cancer Drug Repurposing May 7, 2026
- Three Targets Beyond PSMA in Prostate Cancer Radioligand Therapy May 6, 2026